China's Medtech Regulatory Reforms Yet To Enter Steady Path
Executive Summary
Medical device companies operating in China are still looking for clearer guidance that will help them make the most of the wide-ranging regulatory reforms introduced in the country since 2014.
You may also be interested in...
China Shows More Of An Open Door To Overseas Medtech Industry
China's influence on global medtech regulation and the country's continuing emergence on the world stage will be felt increasingly in the coming years. But while China may be less inclined to exclude big medtech multinationals, it feels no compulsion to harmonize totally with the US and/or EU systems.
Unlocking Legalities: Antitrust Risk Rises In China
A $17.2m fine Chinese regulators imposed on Medtronic may just be the tip of the enforcement iceberg as the country attempts to discipline overseas manufacturers who break new antitrust laws.
China’s Fast-Track Innovative Device Pathway Delivers For Few
Less than 5% of applications for China’s fast-track device pathway have been approved, with the main reason for failure becoming clear.